

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2020/188505 A1

(43) International Publication Date
24 September 2020 (24.09.2020)

(51) International Patent Classification:

A61K 31/519 (2006.01) A61P 13/10 (2006.01)
A61K 45/06 (2006.01)

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/IB2020/052484

(22) International Filing Date:

18 March 2020 (18.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/820,230	18 March 2019 (18.03.2019)	US
62/830,302	05 April 2019 (05.04.2019)	US
62/842,435	02 May 2019 (02.05.2019)	US
62/885,767	12 August 2019 (12.08.2019)	US
62/897,019	06 September 2019 (06.09.2019)	US
62/904,429	23 September 2019 (23.09.2019)	US

(71) Applicant: **UROVANT SCIENCES GMBH** [CH/CH];
Viaduktstrasse 8, 4051 Basel (CH).

(72) Inventor: **MUDD, JR., Paul N.**; c/o Urovant Sciences,
Inc., 5281 California Avenue, Suite #100, Irvine, California
92617 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv))

(54) Title: USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER

(57) Abstract: The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of 75 mg of vibegron per day.



WO 2020/188505 A1